Nemaura Medical is a holding company. Through its subsidiaries, Co. performs medical device research and manufacturing of a continuous glucose monitoring system, named sugarBEAT®. The sugarBEAT® device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients. The sugarBEAT® device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. SugarBEAT® consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that display glucose reading every five minutes via mobile phone. The NMRD stock yearly return is shown above.
The yearly return on the NMRD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NMRD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|